Skip to content
Screener

Other geography segments

FR
$7M-1.6%
CN
$4.56M+1,425%

Similar metrics at other companies

Deere & Company logo
DEUS — Revenue
$7.2B+3.9%
Worthington Enterprises logo
WORUS — Revenue
$222.86M-3.5%
Napco Security Technologies logo
NSSCUS — Revenue
$48.35M+11.2%
FuelCell Energy logo
FCELUS — Revenue
$14.09M-40.0%
Oracle logo
ORCLUS — Revenue
$9.96B+24.2%
Photronics logo
PLABUS — Revenue
$34.16M+11.2%

Other financials

Income statement

See full
Revenue$183.9M+5.4%
Gross profit$93.5M+8.1%
Operating income$39.7M-5.8%
Net income$30.3M-2.2%
EPS (diluted)$0.67+4.7%

Balance sheet

See full
Cash & equivalents$223.6M+19.1%
Total debt$688.5M+5.0%
Total equity$445.5M
Total assets$1.7B+8.0%

Cash flow

See full
Operating cash flow$51.3M+44.2%
CapEx$8.6M-18.7%
Free cash flow$42.7M+70.7%

Valuation

See full
Market cap$916.25M-28.0%
Enterprise value$1.38B-20.6%
P/E11.7×+2.2×
P/S1.3×-0.5×

Profitability

See full
Gross margin47.7%-2.2pp
Operating margin15.7%-9.5pp
Net margin10.8%-7.9pp
FCF margin20.9%+5.4pp

Returns & leverage

See full
Return on equity14.7%
Debt / equity0.2×
Current ratio2.4×-0.9×

Where this comes from

Reported directly by Amphastar Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The source filing: Amphastar Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:50 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001297184-26-000047
Line itemNet Revenues / Three Months Ended / June 30, 2026Net Revenues / Three Months Ended / June 30, 2025Net Revenues / Six Months Ended / June 30, 2026Net Revenues / Six Months Ended / June 30, 2025Long-Lived Assets / June 30, 2026Long-Lived Assets / December 31, 2025
United States$172,342$167,002$331,382$329,592$247,218$206,697
China4,5602997,042380107,268110,055
France7,0017,11316,65014,97034,64036,967
Total$183,903$174,414$355,074$344,942$389,126$353,719

Item 1. Financial Statements (unaudited)

FAQ

What is Amphastar Pharmaceuticals's US — revenue?
Amphastar Pharmaceuticals (AMPH) reported US — revenue of $172.34M in Q2 2026.
How has Amphastar Pharmaceuticals's US — revenue changed year-over-year?
Amphastar Pharmaceuticals's US — revenue increased by 3.2% year-over-year, from $167M to $172.34M.
What is the long-term trend for Amphastar Pharmaceuticals's US — revenue?
Over 4 years (2021 to 2025), Amphastar Pharmaceuticals's US — revenue has grown at a 12.9% compound annual growth rate (CAGR), from $419.87M to $681.42M.
What does US — revenue mean?
This metric represents the total gross sales generated from products sold within the United States geographic segment. It reflects the company's ability to capture market share and monetize its portfolio of injectable, inhalation, and intranasal products through domestic distribution channels. Growth in this figure indicates successful commercial execution and demand for the company's therapeutic offerings in the domestic market.

Ask your AI about Amphastar Pharmaceuticals's us — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude